Skip to main content

Research Repository

See what's under the surface


MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer (2017)
Journal Article
Craze, M. L., Cheung, H., Jewa, N., Coimbra, N. D., Soria, D., El-Ansari, R., …Green, A. R. (in press). MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer. British Journal of Cancer, doi:10.1038/bjc.2017.387

Background: Altered cellular metabolism is a hallmark of cancer and some are reliant on Glutamine for sustained proliferation and survival. We hypothesise that the Glutamine-Proline regulatory axis has a key role in Breast cancer (BC) in the highly p... Read More about MYC regulation of Glutamine-Proline regulatory axis is key in Luminal B breast cancer.

Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer (2017)
Journal Article
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F., Haider, S., Kriplani, D., …Natrajan, R. (2018). Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer. Molecular Cancer Therapeutics, 17(1), 306-315. doi:10.1158/1535-7163.mct-17-0760

Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess t... Read More about Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer.

Reply to Rosen (2017)
Journal Article
Reis-Filho, J. S., Geyer, F. C., Weigelt, B., Rakha, E. A., Ellis, I. O., & Schnitt, S. J. (2017). Reply to Rosen. Modern Pathology, 30(10), 1505-1506. doi:10.1038/modpathol.2017.70

Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations (2017)
Journal Article
El Ansari, R., McIntyre, A., Craze, M. L., Ellis, I. O., Rakha, E. A., & Green, A. R. (in press). Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations. Histopathology, doi:10.1111/his.13334

Cancer cells must alter their metabolism in order to satisfy the demands of necessary energy and cellular building blocks. These metabolic alterations are mediated by many oncogenic changes that affect cellular signalling pathways, which result in su... Read More about Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations.

Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: A Unique Invasive Tumor With Indolent Behavior (2017)
Journal Article
Foschini, M. P., Asioli, S., Foreid, S., Cserni, G., Ellis, I. O., Eusebi, V., & Rosai, J. (2017). Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: A Unique Invasive Tumor With Indolent Behavior. American Journal of Surgical Pathology, 41(7), 887-895. doi:10.1097/pas.0000000000000853

Thirteen cases of invasive solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (BPTC) are reported here. Some cases had long-term follow-up. BPTC is a special type of primary breast neoplasm showing a tri... Read More about Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: A Unique Invasive Tumor With Indolent Behavior.

Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review (2017)
Journal Article
Toss, M., Miligy, I., Thompson, A., Khout, H., Green, A., Ellis, I., & Rakha, E. (2017). Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review. Breast, 35, 151-156. doi:10.1016/j.breast.2017.07.012

The high proportion of ductal carcinoma in situ (DCIS) presented in mammographic screening and the relatively low risk of progression to invasive disease have raised questions related to overtreatment. Following a review of current DCIS management pr... Read More about Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review.

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers (2017)
Journal Article
Klimov, S., Rida, P. C., Aleskandarany, M. A., Green, A. R., Ellis, I. O., Janssen, E. A., …Aneja, R. (2017). Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. British Journal of Cancer, 117(6), 826-834. doi:10.1038/bjc.2017.224

Background: Although distant metastasis (DM) in breast cancer (BC) is the most lethal form of recurrence and the most common underlying cause of cancer related deaths, the outcome following the development of DM is related to the site of metastasis.... Read More about Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.

Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer (2017)
Conference Proceeding
Ojiegbe, S., Joseph, C., Provenzano, E., Caldas, C., Nolan, C., Green, A., …Mukherjee, A. (2017). Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer

Purpose of the study: The mammalian sterile 20-like kinase (MST2/STK3) and its close homologue MST1(STK4) are members of the germinal centre kinase group II (GCK II) family of mitogen-activated protein kinases (MAPK). High STK3 expression is known to... Read More about Elevated expression of STK3 mRNA and protein is associated with poor outcome in invasive breast cancer.

FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype (2017)
Conference Proceeding
Joseph, C., Craze, M. L., Nolan, C., Diez-Rodriguez, M., Green, A. R., Rakha, E., …Mukherjee, A. (2017). FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype

Background: Fork head box P1 (FOXP1) is a FOX family transcription factor influencing ERα;-regulated transcription by interaction with the ERα; related pioneer factor FOXA1. Altered FOXP1 expression is seen in breast and prostate cancers. This study... Read More about FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype.

An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation (2017)
Journal Article
Candido Dos Reis, F. J., Wishart, G. C., Dicks, E. M., Greenberg, D., Rashbass, J., Schmidt, M. K., …Pharoah, P. D. (2017). An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Research, 19(1), doi:10.1186/s13058-017-0852-3

BACKGROUND: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate breast cancer specific morta... Read More about An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections (2017)
Journal Article
Nolan, C. C., Muftah, A. A., Aleskandarany, M. A., Al-kaabi, M. M., Sonbul, S. N., Diez-Rodriguez, M., …Green, A. R. (2017). Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Research and Treatment, 164(2), 341-348. https://doi.org/10.1007/s10549-017-4270-0

Background: Although the prognostic value of Ki67 in breast cancer is well documented, using optimal cut-points for patient stratification, reproducibility of the scoring and interpretation of the results remain a matter of debate particularly when u... Read More about Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.

Phenotypic characterization of breast cancer: the role of CDC42 (2017)
Journal Article
Chrysanthou, E., Gorringe, K. L., Joseph, C., Craze, M. L., Nolan, C. C., Diez-Rodriguez, M., …Mukherjee, A. (2017). Phenotypic characterization of breast cancer: the role of CDC42. Breast Cancer Research and Treatment, 164(2), doi:10.1007/s10549-017-4267-8

Purpose: The molecular landscape of breast cancer (BC), especially of the Luminal A subtype, remains to be fully delineated. Transcriptomic data shows that Luminal A tumours are enriched for aberrant expression of genes in the cell division control 4... Read More about Phenotypic characterization of breast cancer: the role of CDC42.

Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma (2017)
Journal Article
Sonbul, S. N., Gorringe, K. L., Aleskandarany, M. A., Mukherjee, A., Green, A. R., Ellis, I. O., & Rakha, E. A. (2017). Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. Journal of Pathology, 3(2), doi:10.1002/cjp2.65

Some previous studies have reported that the chemokine (C-C motif) receptor 7 (CCR7) plays a role in breast cancer, is associated with lymph node metastasis and drives the site of distant metastasis. However, the impact of its expression on patient o... Read More about Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma.

Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers (2017)
Journal Article
Rakha, E. A., Green, A. R., Aleskandarany, M. A., Ali, R., Hodgson, E. G., Atabani, S., …Madhusudan, S. (2017). Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers. Cancer Immunology Research, 5(4), 292-299. https://doi.org/10.1158/2326-6066.CIR-16-0195

Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We investigated the expression of proteins involved in the DNA damage response (ATM, Chk2), double-strand break repair (BRCA1, BLM, WRN, RECQL4, RECQL5, TOPO... Read More about Clinical impact of tumor DNA repair expression and T-cell infiltration in breast cancers.

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer (2017)
Journal Article
Alexander, A., Karakas, C., Chen, X., Carey, J. P., Yi, M., Bondy, M., …Keyomarsi, K. (2017). Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget, 8, 14897-14911. doi:10.18632/oncotarget.14689

Inflammatory breast cancer (IBC) is a virulent form of breast cancer, and novel treatment strategies are urgently needed. Immunohistochemical analysis of tumors from women with a clinical diagnosis of IBC (n = 147) and those with non-IBC breast cance... Read More about Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.